Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 4/20 | 0.62 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.57 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21056237 | 0.80 | FGFR3 (0.73) | FGFR3FGFR2FGFR1FGFR4BTK | |
| Hydrochloric Acid SCHEMBL21050952 | 0.80 | FGFR3 (0.72) | FGFR3FGFR2FGFR1FGFR4BTK | |
| SCHEMBL25557819 | 0.78 | FGFR2 (0.51) | FGFR3FGFR2FGFR1FGFR4SRC | |
| SCHEMBL21091192 | 0.77 | FGFR3 (0.68) | FGFR3FGFR2FGFR1FGFR4TNK2 | |
| SCHEMBL21131365 | 0.77 | FGFR4 (0.74) | FGFR3FGFR2FGFR1FGFR4TNK2 | |
| Hydrochloric Acid SCHEMBL22352686 | 0.77 | FGFR3 (0.67) | FGFR3FGFR2FGFR1FGFR4TNK2 | |
| SCHEMBL21131562 | 0.77 | FGFR1 (0.81) | FGFR3FGFR2FGFR1FGFR4TNK2 | |
| Hydrochloric Acid SCHEMBL21056241 | 0.77 | FGFR3 (0.67) | FGFR3FGFR2FGFR1FGFR4TNK2 | |
| SCHEMBL22696342 | 0.74 | FGFR1 (0.51) | FGFR3FGFR2FGFR1FGFR4TNK2 | |
| SCHEMBL21131362 | 0.74 | FGFR4 (0.72) | FGFR3FGFR2FGFR1FGFR4BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752631-B2 | Heterocyclic compounds as FGFR inhibitors | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2020-08-25 | — | — | US | disclosed |
| US-20190177333-A1 | HETEROCYCLIC COMPOUNDS AS FGFR INHIBITOR | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177333-A1 | HETEROCYCLIC COMPOUNDS AS FGFR INHIBITOR | FGFR1, FGFR3, FGFR2 | FGFR3 2/4885FGFR2 3/4885FGFR1 1/4885 |
| US-10752631-B2 | Heterocyclic compounds as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | FGFR3 2/4885FGFR2 3/4885FGFR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.